In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litig., No. 18-md-2819 (E.D.N.Y.)

In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litig., No. 18-md-2819 (E.D.N.Y.)

In the Restasis case, Faruqi & Faruqi represents a proposed class of direct purchasers of Restasis. The direct purchasers alleged that the drug’s manufacturer, Allergan, Inc., delayed entry of a generic version of Restasis by procuring patents by fraud, listing those fraudulently acquired patents in the Orange Book, filing serial sham petitions with the FDA, and transferring ownership of the fraudulently acquired patents to the Saint Regis Mohawk Tribe and asserting the Tribe’s sovereign immunity. A settlement of $51 million was reached with Allergan in February 2020 and was finally approved by the court on October 7, 2020.

Details
Filed On: December 11, 2017
Counsel
Joseph T. Lukens
jlukens@faruqilaw.com
Phone (215) 277-5770
Fax (215) 277-5771
Peter Kohn
pkohn@faruqilaw.com
Phone (215) 277-5770
Fax (215) 277-5771
Office
Pennsylvania
1617 JFK Boulevard, Suite 1550 Philadelphia Pennsylvania 19103
Phone (215) 277-5770
Fax (215) 277-5771

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771